Status:
RECRUITING
Genome Analysis Across Populations in Inflammatory Bowel Disease
Lead Sponsor:
Mount Sinai Hospital, Canada
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Ulcerative Colitis
Healthy
Eligibility:
All Genders
Brief Summary
Objective: To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD within affected populations.
Detailed Description
Background: Inflammatory bowel disease (IBD) is a chronic, and often disabling, disorder of the intestines characterized by dysregulation of mucosal immune response. Recent data suggests that the inc...
Eligibility Criteria
Inclusion
- Subjects: diagnosed with Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, IBD-undetermined)
- Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U))
- Healthy controls: no personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss
- Any age
Exclusion
- \- Subjects with other gastrointestinal conditions not meeting the above IBD or Healthy Control criteria
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06042387
Start Date
May 1 2022
End Date
September 1 2027
Last Update
March 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sinai Health System
Toronto, Ontario, Canada, M5G 1X5